

## References

- [1] Daniel DG, Busner J, Kott A. Challenges and Putative Approaches to Improving Signal Detection in Schizophrenia Clinical Trials. *J Schizophr Res.* 2024; 10(1): 1047
- [2] Leucht S, Chaimani A, Mavridis D, Leucht C, Huhn M, Helfer B, Samara M, Cipriani A, Geddes JR, Davis JM. Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. *Neuropsychopharmacology.* 2019 Oct;44(11):1955-1966. doi: [10.1038/s41386-019-0440-6](https://doi.org/10.1038/s41386-019-0440-6). Epub 2019 Jun 18. PMID: 31212302; PMCID: PMC6785090.
- [3] Marder, Stephen R., MD, Michael Davidson, MD, Silvia Zaragoza, PhD, Alan Kott, MUDr, Anzalee Khan, PhD, Xingmei Wang, MS, Dawn I. Velligan, PhD, Daniel Umbricht, PhD, Remy Luthringer, PhD, and David Daniel, MD. Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements, *Schizophrenia Bulletin Open*, Volume 1, Issue 1, January 2020, sgz001, <https://doi.org/10.1093/schizbullopen/sgz001>
- [4] Fraguas D, Diaz-Caneja CM, Pina-Camacho L, Umbricht D, Arango C. Predictors of placebo response in pharmacological clinical trials of negative symptoms in schizophrenia: a meta-regression analysis. *Schizophr Bull* 2019;45(1):57–68. <https://pubmed.ncbi.nlm.nih.gov/29370436/>.
- [5] West MD, Daniel DG, Opler M, Wise-Rankovic A, Kalali A. CNS Summit Rater Training and Certification Committee Consensus recommendations on rater training and certification. *Innov Clin Neurosci.* 2014 Nov-Dec;11(11-12):10-3. PMID: 25621182; PMCID: PMC4301026. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301026/>.
- [6] Rabinowitz, J., Schooler, N.R., Anderson, A.E., Ayearst, L.E., Daniel, D.G., Davidson, M.H., Khan, A., Kinon, B.J., Ménard, F., Opler, L.A., Opler, M., Severe, J.B., Williamson, D., Yavorsky, C., & Zhao, J. (2017). Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). *Schizophrenia Research*, 190, 74-76. <https://pubmed.ncbi.nlm.nih.gov/28285023/>
- [7] Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. *Biol Psychiatry.* 2000 Apr 15;47(8):762-6. doi: 10.1016/s0006-3223(00)00837-4. PMID: 10773186. <https://pubmed.ncbi.nlm.nih.gov/10773186/>.
- [8] Daniel D and Kott A: Do Rater Certification Procedures Identify Poor Raters? Poster presentation at Fall Meeting of the Annual International Society for CNS Clinical trials and

Methodology (ISCTM) Scientific Meeting. Philadelphia, PA, September 30-October 2, 2013.  
<https://isctm.org/meeting-archives/>

[9] Kenneth A. Kobak, Mark G.A. Opler, Nina Engelhardt: PANSS rater training using Internet and videoconference: Results from a pilot study, *Schizophrenia Research*, Volume 92, Issues 1–3, 2007, Pages 63-67, ISSN 0920-9964,  
<https://doi.org/10.1016/j.schres.2007.01.011>.

[10] Williams J., Popp, D., Kobak, K., & Detke, M. (2012). P-640— the Power of Expectation Bias. *European Psychiatry*, 27(S1), 1-1. doi:[10.1016/S0924-9338\(12\)74807-1](https://doi.org/10.1016/S0924-9338(12)74807-1)

[11] Nielsen CM, Kølbaek P, Dines D, Opler M, Correll CU, Østergaard SD. Are informants required to obtain valid ratings on the Positive and Negative Syndrome Scale (PANSS)? *Schizophrenia (Heidelb)*. 2023 Aug 31;9(1):54. doi: [10.1038/s41537-023-00378-5](https://doi.org/10.1038/s41537-023-00378-5). PMID: 37653026; PMCID: PMC10471695.

[12] Cohen EA, Hassman HH, Ereshefsky L, Walling DP, Grindell VM, Keefe RSE, Wyka K, Horan WP. Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. *Neuropsychopharmacology*. 2021 Mar;46(4):844-850. doi: [10.1038/s41386-020-00911-5](https://doi.org/10.1038/s41386-020-00911-5). Epub 2020 Nov 26. PMID: 33244149; PMCID: PMC8026614.

[13] Kott A, and Daniel D: Early Indicators of Poor Data quality in Schizophrenia Clinical Trials. Poster Presented at 12th Annual Meeting of the International Society for Clinical Trials Methodology (ISCTM), Feb 16-18, 2016, Washington, DC. <https://isctm.org/meeting-archives/>

[14] Kott A, Brannan S, Wang X, Daniel D. The Impact of Aberrant Data Variability on Drug-Placebo Separation and Drug/Placebo Response in an Acute Schizophrenia Clinical Trial. *Schizophr Bull Open*. 2021 Aug 7;2(1): sgab037. doi: [10.1093/schizbullopen/sgab037](https://doi.org/10.1093/schizbullopen/sgab037). PMID: 34901869; PMCID: PMC8650072.

[15] Umbricht, D.S., Kott, A., & Daniel, D.G. (2020). The Effects of Erratic Ratings on Placebo Response and Signal Detection in the Roche Bitopertin Phase 3 Negative Symptom Studies—A Post Hoc Analysis. *Schizophrenia Bulletin Open*.  
<https://doi.org/10.1093/schizbullopen/sgaa040>

[16] Kott A, Wang X and Daniel D: Exploring the Association of PANSS Rater Change with Extreme Within-Subject Variability in Schizophrenia Clinical Trials. Poster Presented at the ISCTM 15th Annual Meeting, February 19-21, 2019, Washington, DC.  
[https://isctm.org/public\\_access/Feb2019/Abstracts/Kott-abstract.pdf](https://isctm.org/public_access/Feb2019/Abstracts/Kott-abstract.pdf)

[17] Daniel, David G.; Kott, Alan (2018): Does variation in the time of day of PANSS assessment effect symptom severity? Poster presentation. International Society for CNS Clinical Trials and Methodology (ISCTM). Washington, D.C., USA, 2/20/2018.

[https://isctm.org/public\\_access/19th\\_Annual/Abstract/Daniel\\_Abstract.pdf](https://isctm.org/public_access/19th_Annual/Abstract/Daniel_Abstract.pdf)

[18] Daniel DG and Kott A: Risk-based Monitoring for Aberrant Rating Patterns and Patient Selection Anomalies in Trials. Poster presented at the Schizophrenia International Research Society (SIRS) Florence Italy, April 5-9, 2014.

[http://d.plnk.co/SIRS/2014/PROGRAMMA\\_SIRS\\_2014\\_11.pdf](http://d.plnk.co/SIRS/2014/PROGRAMMA_SIRS_2014_11.pdf)

[19] Echevarria, Barbara et al. "M42. Independent review and monitoring improves quality of PANSS data in global clinical trials." Schizophrenia Bulletin vol. 46, Suppl 1 (2020): S150. doi:10.1093/schbul/sbaa030.354

[20] Kott A, Daniel DG. Effects of PANSS audio/video recordings on the presence of identical scorings across visits. Eur Neuropsychopharmacology. 2015;25:S543–S544.

[21] Daniel D, Wang X and Kott A: eCOA Increases Data Quality Compared to Audio/video recording alone in schizophrenia clinical trials. Poster presented at International Society for CNS Clinical Trials and Methodology (ISCTM), Washington, DC, February 19-21, 2020.

[https://isctm.org/public\\_access/Feb2020/Posters/Kott-Poster.pdf](https://isctm.org/public_access/Feb2020/Posters/Kott-Poster.pdf)

[22] Targum SD, Murphy C, Breier A, Brannan SK. Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial. J Psychiatr Res. 2021 Dec;144:241-246. doi: 10.1016/j.jpsychires. 2021.10.027. Epub 2021 Oct 21. PMID: 34700212.

[23] Targum SD, Pendergrass JC, Murphy C. Audio-digital recordings to assess ratings reliability in clinical trials of schizophrenia. Schizophr Res. 2021 Jun;232:54-60. doi: 10.1016/j.schres.2021.05.004. Epub 2021 May 17. PMID: 34015556.

[24] Harvey PD, Miller ML, Moore RC, Depp CA, Parrish EM, Pinkham AE. Capturing Clinical Symptoms with Ecological Momentary Assessment: Convergence of Momentary Reports of Psychotic and Mood Symptoms with Diagnoses and Standard Clinical Assessments. Innov Clin Neurosci. 2021 Jan 1;18(1-3):24-30. PMID: 34150360; PMCID: PMC8195558.

[25] Kott A, Curtin D, Chen Tackett Z, Daniel D: Exploring the Utility of Data Analytics for Identification and Management of Data Quality Concerns in ePRO Data. Poster Presented at the 2019 American Society for Clinical Psychopharmacology (ASCP) Meeting, Scottsdale, Arizona, May 28-31, 2019

[26] Kott A, Xingmei Wang, Emanuel Pintilii, Andrei Iacob: Using Machine Learning to Identify at Risk Sites in Acute Schizophrenia Clinical Trials. Journal for Clinical Studies, February 24, 2022; Volume 14, Issue 1. 24-26.

- [27] Boesen K, Gøtzsche PC, Ioannidis JPA. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations. *Epidemiol Psychiatr Sci.* 2021 Apr 30;30:e35. doi: [10.1017/S2045796021000147](https://doi.org/10.1017/S2045796021000147). PMID: 33926608; PMCID: PMC8157504.
- [28] McClellan, J., Stock, S. American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *Journal of the American Academy of Child & Adolescent Psychiatry*, 52(9): 976-990.
- [29] Busner, J. (2013). Challenges in child and adolescent psychopharmacology clinical trials. *Child and Adolescent Psychopharmacology News*, 18(3):1-4.  
<https://guilfordjournals.com/doi/10.1521/capn.2013.18.3.1>
- [30] Findling, R.L., Youngstrom, E.A., Frazier, J.A., Sikich, L., Daniel, D.G., Busner, J. (2023). An optimized version of the Positive and Negative Symptoms Scale (PANSS) for pediatric trials. *Journal of the American Academy of Child and Adolescent Psychiatry*. 62 (4): 427-434.
- [31] Busner, J., Daniel, D.G., Findling, R.L. Identification of PANSS items of particular challenge to raters in adolescent schizophrenia clinical trials. Presented as a poster at the Autumn Conference of the International Society for CNS Clinical Trials Methodology, Philadelphia, PA, September 30-October 2, 2013.
- [32] Busner, J., Daniel, D.G., Findling, R.L. Identification of PANSS items of particular challenge to raters in adolescent schizophrenia clinical trials: Expansion of initial findings. Presented at the 2021 Society for International Research in Schizophrenia (SIRS) (virtual) annual meeting, April 18-21, 2021
- [33] Findling, R.L., Youngstrom, E.A., Frazier, J.A., Sikich, L., Daniel, D.G., Busner, J. (2023). An optimized version of the Positive and Negative Symptoms Scale (PANSS) for pediatric trials. *Journal of the American Academy of Child and Adolescent Psychiatry*. 62 (4): 427-434.
- [34] Youngstrom, E.A., Langfus, J.A., Busner, J., Daniel, D.G., Findling, R.F. Reliability and Accuracy of Scores Using 20 or 10-item short forms of the Positive and Negative Symptoms Scale (PANSS) Replicated in 3 Large Outpatient Trials. Accepted as an oral presentation for the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, October, 2023, New York, NY.
- [35] Busner, J., Youngstrom, E.A., Langfus, J.A., Daniel, D.G., Findling, R. L. (b) Replicating and extending the reliability, criterion validity, and treatment sensitivity of the PANSS10 and

PANSS20 for pediatric trials. Presented as a poster presentation at the American Society of Clinical Psychopharmacology (formerly NCDEU) annual meeting, May 29-June 2, 2023, Miami, Florida.

[36] Busner, J., Daniel, D.G., Atkinson, S.D., Findling, R.L. (a) Development of a child and adolescent eCOA guided interview for the PANSS interview for assessing psychosis in clinical trials. Presented as a poster at the American Society of Clinical Psychopharmacology (ASCP), formerly NCDEU, Annual Meeting, Miami, FL., May 25-29, 2020.